Liver Transplantation for Hepatocellular Carcinoma in Young Adults: A United Network for Organ Sharing Study

被引:3
作者
Thomas, Stefanie M. [1 ,2 ]
Moke, Diana [1 ]
Lopez, Rocio [3 ]
Hanna, Rabi [4 ]
Kabbany, Mohammad Nasser [5 ]
Alkhouri, Naim [5 ,6 ]
机构
[1] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA
[3] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA
[4] Cleveland Clin Childrens, Dept Pediat Hematol Oncol & Blood & Marrow Transp, Cleveland, OH USA
[5] Cleveland Clin, Dept Pediat Gastroenterol & Hepatol, Cleveland, OH 44106 USA
[6] Cleveland Clin, Digest Dis Inst, Cleveland, OH 44106 USA
关键词
hepatitis B virus; model for end-stage liver disease; surgical oncology; CLINICAL CHARACTERISTICS; SURVIVAL; PROGNOSIS; MORTALITY; FEATURES; COHORT; IMPACT;
D O I
10.1089/jayao.2016.0048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Orthotopic liver transplantation (OLT) is curative for hepatocellular carcinoma (HCC). HCC is typically a disease of older adults (OAs); therefore, characteristics and outcomes of OLT for young adults (YAs) (ages 18-40) are not described. The objective of this study was to assess the characteristics and outcomes of YAs with HCC receiving OLT and compare these to OAs (ages >40 years). Methods: YAs with HCC who had OLT from the United Network for Organ Sharing (UNOS) database were included in this study. As a comparison group, OAs with HCC were matched 4:1 to the YA group. Descriptive statistics of demographics, comorbidities, and outcomes were generated. Kaplan-Meier product limit estimates were used to assess patient and graft survival. Conditional logistic regression and Cox proportional hazards frailty models were used to compare the groups. Results: A total of 464 YAs received OLT for HCC. The most common underlying liver diseases were hepatitis C virus (21.3%), hepatitis B virus (HBV, 15.5%), and autoimmune/cholestatic disease (12.3%). An increased number of YAs received OLT for HCC after implementation of model for end-stage liver disease scoring. One thousand two hundred eighty OAs served as the comparison group. Post-transplant 5-year survival was 73.1% in YAs with a retransplantation rate of 7.8%. In OAs, survival and retransplantation rates were lower (68.6% p=0.093; 4.3% p=0.001). Conclusion: Four hundred sixty-four YAs with HCC received OLT in the UNOS database. Compared to the older population, survival and retransplantation rates were higher. HBV, which is vaccine preventable, is a frequent contributor to HCC in YAs.
引用
收藏
页码:286 / 293
页数:8
相关论文
共 24 条
  • [1] Liver transplantation for nonalcoholic steatohepatitis in young patients
    Alkhouri, Naim
    Hanouneh, Ibrahim A.
    Zein, Nizar N.
    Lopez, Rocio
    Kelly, Dympna
    Eghtesad, Bijan
    Fung, John J.
    [J]. TRANSPLANT INTERNATIONAL, 2016, 29 (04) : 418 - 424
  • [2] Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
    Altekruse, Sean F.
    Henley, S. Jane
    Cucinelli, James E.
    McGlynn, Katherine A.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) : 542 - 553
  • [3] Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
    Altekruse, Sean F.
    McGlynn, Katherine A.
    Reichman, Marsha E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1485 - 1491
  • [4] The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis
    Ascha, Mustafa S.
    Hanouneh, Ibrahim A.
    Lopez, Rocio
    Tamimi, Tarek Abu-Rajab
    Feldstein, Ariel F.
    Zein, Nizar N.
    [J]. HEPATOLOGY, 2010, 51 (06) : 1972 - 1978
  • [5] Optimal matching with a variable number of controls vs. a fixed number of controls for a cohort study: trade-offs
    Cepeda, MS
    Boston, R
    Farrar, JT
    Strom, BL
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) : 230 - 237
  • [6] Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome
    Chang, Pik-Eu
    Ong, Wai-Choung
    Lui, Hock-Foong
    Tan, Chee-Kiat
    [J]. JOURNAL OF GASTROENTEROLOGY, 2008, 43 (11) : 881 - 888
  • [7] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386
  • [8] Management of hepatocellular carcinoma
    Fitzmorris, P.
    Shoreibah, M.
    Anand, B. S.
    Singal, A. K.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) : 861 - 876
  • [9] Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand?
    Fujiki, Masato
    Aucejo, Federico
    Choi, Minsig
    Kim, Richard
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (18) : 5308 - 5319
  • [10] Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]